Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4793309 | 0.81 | HSD11B1 (0.38) | HSD11B1KMT2ACYP2D6OPRM1OPRD1 | |
| SCHEMBL14671520 | 0.81 | KMT2A (0.41) | HSD11B1KMT2ACYP2D6OPRM1OPRD1 | |
| SCHEMBL4749063 | 0.77 | MAPT (0.40) | HSD11B1KMT2ACYP2D6OPRL1HPGD | |
| SCHEMBL2670110 | 0.77 | MAPT (0.40) | HSD11B1KMT2ACYP2D6OPRL1HPGD | |
| SCHEMBL2670114 | 0.77 | MAPT (0.40) | HSD11B1KMT2ACYP2D6OPRL1HPGD | |
| SCHEMBL4748532 | 0.74 | HSD11B1 (0.39) | HSD11B1KMT2ACYP2D6OPRM1OPRD1 | |
| SCHEMBL15099815 | 0.72 | HSD11B1 (0.42) | HSD11B1KMT2ACYP2D6OPRM1OPRD1 | |
| SCHEMBL739714 | 0.72 | HSD11B1 (0.42) | HSD11B1KMT2ACYP2D6OPRM1OPRD1 | |
| SCHEMBL2670782 | 0.72 | KMT2A (0.37) | KMT2AOPRL1HPGDLMNAMAPK1 | |
| SCHEMBL4748562 | 0.72 | CYP2C19 (0.38) | HSD11B1KMT2ACYP2D6OPRL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | HSD11B1 3535/4885KMT2A 2847/4885CYP2D6 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.